DBZ Onkologie GmbH

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Triple-negative breast cancer2 trials
• Metastatic breast cancer1 trial

Phase

• Phase 32 trials
• Phase 21 trial

Status

• Recruiting3 trials

Lead sponsor

• BioNTech SE1 trial
• GBG Forschungs GmbH1 trial
• Women's Cancer Study Group GmbH1 trial

Running trials

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Recruiting

  Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

  NCT06201234· Phase 2· GBG Forschungs GmbH· Source

• Recruiting

  NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

  NCT06081244· Phase 3· Women's Cancer Study Group GmbH· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Triple-negative breast cancer2 recruiting
• Metastatic breast cancer1 recruiting